A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy
Breast cancer is the most common cancer in women worldwide. A new promising anti-cancer therapy involves the use of monoclonal antibodies specific for target tumor-associated antigens (TAAs). A TAA of interest for immunotherapy of Triple Negative Breast Cancer (TNBC) is nucleolin (NCL), a multifunct...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349967/ https://www.ncbi.nlm.nih.gov/pubmed/27894092 http://dx.doi.org/10.18632/oncotarget.13522 |
_version_ | 1782514572228296704 |
---|---|
author | D'Avino, Chiara Palmieri, Dario Braddom, Ashley Zanesi, Nicola James, Cindy Cole, Sara Salvatore, Francesco Croce, Carlo M. De Lorenzo, Claudia |
author_facet | D'Avino, Chiara Palmieri, Dario Braddom, Ashley Zanesi, Nicola James, Cindy Cole, Sara Salvatore, Francesco Croce, Carlo M. De Lorenzo, Claudia |
author_sort | D'Avino, Chiara |
collection | PubMed |
description | Breast cancer is the most common cancer in women worldwide. A new promising anti-cancer therapy involves the use of monoclonal antibodies specific for target tumor-associated antigens (TAAs). A TAA of interest for immunotherapy of Triple Negative Breast Cancer (TNBC) is nucleolin (NCL), a multifunctional protein, selectively expressed on the surface of cancer cells, which regulates the biogenesis of specific microRNAs (miRNAs) involved in tumor development and drug-resistance. We previously isolated a novel human anti-NCL scFv, called 4LB5, that is endowed with selective anti-tumor effects. Here we report the construction and characterization of a novel immunoRNase constituted by 4LB5 and a human pancreatic RNase (HP-RNase) called “4LB5-HP-RNase”. This immunoRNase retains both the enzymatic activity of human pancreatic RNase and the specific binding of the parental scFv to a panel of surface NCL-positive breast cancer cells. Notably, 4LB5-HP-RNase dramatically and selectively reduced the viability and proliferation of NCL-positive tumor cells in vitro and in vivo. Specifically, it induced apoptosis and reduced the levels of the tumorigenic miRNAs miR-21, -221 and -222. Thus, this novel immunoagent could be a valuable tool for the treatment of TNBC patients ineligible for currently available targeted treatments. |
format | Online Article Text |
id | pubmed-5349967 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53499672017-04-06 A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy D'Avino, Chiara Palmieri, Dario Braddom, Ashley Zanesi, Nicola James, Cindy Cole, Sara Salvatore, Francesco Croce, Carlo M. De Lorenzo, Claudia Oncotarget Research Paper Breast cancer is the most common cancer in women worldwide. A new promising anti-cancer therapy involves the use of monoclonal antibodies specific for target tumor-associated antigens (TAAs). A TAA of interest for immunotherapy of Triple Negative Breast Cancer (TNBC) is nucleolin (NCL), a multifunctional protein, selectively expressed on the surface of cancer cells, which regulates the biogenesis of specific microRNAs (miRNAs) involved in tumor development and drug-resistance. We previously isolated a novel human anti-NCL scFv, called 4LB5, that is endowed with selective anti-tumor effects. Here we report the construction and characterization of a novel immunoRNase constituted by 4LB5 and a human pancreatic RNase (HP-RNase) called “4LB5-HP-RNase”. This immunoRNase retains both the enzymatic activity of human pancreatic RNase and the specific binding of the parental scFv to a panel of surface NCL-positive breast cancer cells. Notably, 4LB5-HP-RNase dramatically and selectively reduced the viability and proliferation of NCL-positive tumor cells in vitro and in vivo. Specifically, it induced apoptosis and reduced the levels of the tumorigenic miRNAs miR-21, -221 and -222. Thus, this novel immunoagent could be a valuable tool for the treatment of TNBC patients ineligible for currently available targeted treatments. Impact Journals LLC 2016-11-23 /pmc/articles/PMC5349967/ /pubmed/27894092 http://dx.doi.org/10.18632/oncotarget.13522 Text en Copyright: © 2016 D'Avino et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper D'Avino, Chiara Palmieri, Dario Braddom, Ashley Zanesi, Nicola James, Cindy Cole, Sara Salvatore, Francesco Croce, Carlo M. De Lorenzo, Claudia A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy |
title | A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy |
title_full | A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy |
title_fullStr | A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy |
title_full_unstemmed | A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy |
title_short | A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy |
title_sort | novel fully human anti-ncl immunornase for triple-negative breast cancer therapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349967/ https://www.ncbi.nlm.nih.gov/pubmed/27894092 http://dx.doi.org/10.18632/oncotarget.13522 |
work_keys_str_mv | AT davinochiara anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT palmieridario anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT braddomashley anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT zanesinicola anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT jamescindy anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT colesara anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT salvatorefrancesco anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT crocecarlom anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT delorenzoclaudia anovelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT davinochiara novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT palmieridario novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT braddomashley novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT zanesinicola novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT jamescindy novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT colesara novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT salvatorefrancesco novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT crocecarlom novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy AT delorenzoclaudia novelfullyhumanantinclimmunornasefortriplenegativebreastcancertherapy |